Abstract
The Society of Behavioral Medicine (SBM) supports the United States Preventive Services Task Force (USPSTF) recommendation of low-dose computed tomography (LDCT) screening of the chest for eligible populations to reduce lung cancer mortality. Consistent with efforts to translate research findings into real-world settings, SBM encourages health-care providers and health-care systems to (1) integrate evidence-based tobacco treatment as an essential component of LDCT-based lung cancer screening, (2) examine the structural barriers that may impact screening uptake, and (3) incorporate shared decision-making as a clinical platform to facilitate consultations and engagement with individuals at high risk for lung cancer about the potential benefits and harms associated with participation in a lung cancer screening program. We advise policy makers and legislators to support screening in high-risk populations by continuing to (1) expand access to high quality LDCT-based screening among underserved high-risk populations, (2) enhance cost-effectiveness by integrating evidence-based tobacco treatments into screening in high-risk populations, and (3) increase funding for research that explores implementation science and increased public awareness and access of diverse populations to participate in clinical and translational research.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Cancer Society. (2016). What are the key statistics about lung cancer? Retrieved from http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-key-statistics
Aberle, D. R., Adams, A. M., Berg, C. D., Black, W. C., Clapp, J. D., & Sicks, J. D. (2011). Reduced lung-cancer mortality with low-dose computed tomography screening. N Engl J Med, 365(5), 395–409.
American Lung Association (2016). Lung cancer screening. Retrieved from http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/lung-cancer/diagnosing-and-treating/lung-cancer-screening.html
Moyer, V. (2014). Screening for lung cancer: U.S. Preventative Services Task Force recommendation statement. Ann Intern Med, 160(5), 330–338.
Centers for Medicare & Medicaid Services. (2015). Decision making for screening for lung cancer with low dose computed tomography (LDCT) (CAG-00439N). Retrieved from https://www.cms.gov/medicare-coverage-database/details/nca-decision memo.aspx?
Zonderman, A. B., Ejiogu, N., Norbeck, J., & Evans, M. K. (2014). The influence of health disparities on targeting cancer prevention efforts. Am J Prev Med, 46(3 Suppl 1), S87–S97.
Centers for Disease Control and Prevention. Lung cancer: risk factors. http://www.cdc.gov/cancer/lung/basic_info/risk_factors.htm
Fiore M. Tobacco use and dependence guideline panel: treating tobacco use and dependence: 2008 update. Rockville, MD: U.S. Dept. of Health and Human Services, Public Health Service, 2008.
Fucito, I. M., Czabafy, S., Hendricks, P. S., Kotsen, C., Richardson, D., & Toll, B. A. (2016). Pairing smoking-cessation services with lung cancer screening: a clinical guideline from the association for the treatment of tobacco use and dependence and the society for research on nicotine and tobacco. Cancer, 122, 1150–1159.
Munshi, V., & McMahon, P. (2013). Importance of smoking cessation in a lung cancer screening program. Current Surgical Reports, 1(4), 242–248.
Ostroff, J. S., Buckshee, N., Mancuso, C. A., Yankelevitz, D. F., & Henschke, C. I. (2001). Smoking cessation following CT screening for early detection of lung cancer. Prev Med, 33(6), 613–621.
Park, E. R., Ostroff, J. S., Rakowski, W., et al. (2009). Risk perceptions among participants undergoing lung cancer screening: baseline results from the National Lung Screening Trial. Ann Behav Med, 37(3), 268–279.
McMahon, P. M., Kong, C. Y., Bouzan, C., Weinstein, M. C., Cipriano, L. E., Tramontano, A. C., et al. (2011). Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol, 6(11), 1841–1848.
Villanti, A. C., Jiang, Y., Abrams, D. B., & Pyenson, B. S. (2013). A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions. PLoS ONE, 8(8), e71379.
Bach, P. B., Mirkin, J. N., Oliver, T. K., et al. (2012). Benefits and harms of CT screening for lung cancer: a systematic review. J Am Med Assoc, 307(22), 2418–2429.
Mazzone, P., Powell, C. A., Arenberg, D., Bach, P., Detterbeck, F., Gould, M. K., et al. (2015). Components necessary for high-quality lung cancer screening: American College of Chest Physicians and American Thoracic Society Policy Statement. Chest, 147(2), 295–303.
Acknowledgment
This manuscript was supported, in part, by the National Institutes of Health’s National Cancer Institute, Grant Numbers U54CA202995, U54CA202997, U54CA203000, and R21 CA173880. This manuscript was also supported in part by the Kentucky Lung Cancer Research Program P02 415 1400004000 and Bristol-Myers Squibb Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the Kentucky Lung Cancer Research Program nor Bristol-Myers Squibb Foundation. The authors wish to gratefully acknowledge the expert review provided by the Society of Behavioral Medicine’s Health Policy Committee, the Cancer Special Interest Group, and the Health Decision Making Special Interest Group.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Author disclosures
The findings reported have not been previously published and the manuscript is not being simultaneously submitted elsewhere.
Information in the article was previously reported to the Society of Behavioral Medicine (SBM). The authors have full control of all primary data and they agree to allow the journal to review the data if requested. The acknowledgement section indicates all funding sources that support in part the information in the manuscript. There are no conflicts of interest to report. The manuscript does not contain any information that would violate human rights nor does the manuscript have any impact on the welfare of animals. No IRB approval was required nor was informed consent required as the manuscript does not contact any information collected from human subject research. This manuscript does not violate the ethical standards of the declaration of Helsinki as it does not involve any human subjects research.
Additional information
Implications
Practice: Health-care providers and health-care systems should employ evidence-based practices to incorporate tobacco cessation into lung cancer screening programs using LDCT along with the use of shared decision-making to ensure high-risk populations have a clear understanding of risk and benefits of screening.
Policy: Policy makers and legislators should support expanded resources to ensure cost-effective screening and tobacco cessation programs along with expanding policies to address structural barriers that impact screening access and uptake in high-risk populations to improve compliance.
Research: SBM advocates for research that examines the incorporation of implementation science to explore structural barriers that impact access, awareness, uptake, and adherence to tobacco cessation and LDCT screening for lung cancer in high-risk populations and also strongly encourages research to include racially and ethnically diverse populations in the participation of lung cancer screening trials.
About this article
Cite this article
Watson, K.S., Blok, A.C., Buscemi, J. et al. Society of Behavioral Medicine supports implementation of high quality lung cancer screening in high-risk populations. Behav. Med. Pract. Policy Res. 6, 669–671 (2016). https://doi.org/10.1007/s13142-016-0440-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13142-016-0440-6